Cargando…
Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
It was recently reported that frailty status can negatively influence the clinical course of patients with inflammatory bowel diseases (IBDs). Our recent study demonstrated that 20% of patients with an IBD are frail, and disease activity increases the risk of frailty. In the present study, we prospe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095533/ https://www.ncbi.nlm.nih.gov/pubmed/37048741 http://dx.doi.org/10.3390/jcm12072658 |
_version_ | 1785024106640441344 |
---|---|
author | Salvatori, Silvia Marafini, Irene Franchin, Martina Lavigna, Diletta Brigida, Mattia Venuto, Chiara Biancone, Livia Calabrese, Emma Giannarelli, Diana Monteleone, Giovanni |
author_facet | Salvatori, Silvia Marafini, Irene Franchin, Martina Lavigna, Diletta Brigida, Mattia Venuto, Chiara Biancone, Livia Calabrese, Emma Giannarelli, Diana Monteleone, Giovanni |
author_sort | Salvatori, Silvia |
collection | PubMed |
description | It was recently reported that frailty status can negatively influence the clinical course of patients with inflammatory bowel diseases (IBDs). Our recent study demonstrated that 20% of patients with an IBD are frail, and disease activity increases the risk of frailty. In the present study, we prospectively monitored this subgroup of frail patients, assessed whether the frailty status was reversible, and analyzed factors associated with frailty reversibility. Of the sixty-four frail patients with IBD enrolled, five (8%) were lost during the follow-up period and one (2%) underwent a colectomy. Eleven out of the fifty-eight (19%) patients maintained a frail phenotype during a median follow-up of 8 months (range 6–19 months), and thirty-five (60%) and twelve (21%) became pre-frail or fit, respectively. A comparison of the 58 patients at baseline and at the end of the study showed that frail phenotype reversibility occurred more frequently in patients who achieved clinical remission. A multivariate analysis showed that the improvement of the frail phenotype was inversely correlated with the persistence of clinically active disease (OR:0.1; 95% CI: 0.02–0.8) and a history of extra-intestinal manifestations (OR:0.1; 95% CI: 0.01–0.6) and positively correlated with the use of biologics (OR: 21.7; 95% CI: 3.4–263). Data indicate that the frail phenotype is a reversible condition in most IBD patients, and such a change relies on the improvement in disease activity. |
format | Online Article Text |
id | pubmed-10095533 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100955332023-04-13 Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases Salvatori, Silvia Marafini, Irene Franchin, Martina Lavigna, Diletta Brigida, Mattia Venuto, Chiara Biancone, Livia Calabrese, Emma Giannarelli, Diana Monteleone, Giovanni J Clin Med Article It was recently reported that frailty status can negatively influence the clinical course of patients with inflammatory bowel diseases (IBDs). Our recent study demonstrated that 20% of patients with an IBD are frail, and disease activity increases the risk of frailty. In the present study, we prospectively monitored this subgroup of frail patients, assessed whether the frailty status was reversible, and analyzed factors associated with frailty reversibility. Of the sixty-four frail patients with IBD enrolled, five (8%) were lost during the follow-up period and one (2%) underwent a colectomy. Eleven out of the fifty-eight (19%) patients maintained a frail phenotype during a median follow-up of 8 months (range 6–19 months), and thirty-five (60%) and twelve (21%) became pre-frail or fit, respectively. A comparison of the 58 patients at baseline and at the end of the study showed that frail phenotype reversibility occurred more frequently in patients who achieved clinical remission. A multivariate analysis showed that the improvement of the frail phenotype was inversely correlated with the persistence of clinically active disease (OR:0.1; 95% CI: 0.02–0.8) and a history of extra-intestinal manifestations (OR:0.1; 95% CI: 0.01–0.6) and positively correlated with the use of biologics (OR: 21.7; 95% CI: 3.4–263). Data indicate that the frail phenotype is a reversible condition in most IBD patients, and such a change relies on the improvement in disease activity. MDPI 2023-04-03 /pmc/articles/PMC10095533/ /pubmed/37048741 http://dx.doi.org/10.3390/jcm12072658 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salvatori, Silvia Marafini, Irene Franchin, Martina Lavigna, Diletta Brigida, Mattia Venuto, Chiara Biancone, Livia Calabrese, Emma Giannarelli, Diana Monteleone, Giovanni Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases |
title | Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases |
title_full | Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases |
title_fullStr | Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases |
title_full_unstemmed | Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases |
title_short | Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases |
title_sort | reversibility of frail phenotype in patients with inflammatory bowel diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10095533/ https://www.ncbi.nlm.nih.gov/pubmed/37048741 http://dx.doi.org/10.3390/jcm12072658 |
work_keys_str_mv | AT salvatorisilvia reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT marafiniirene reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT franchinmartina reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT lavignadiletta reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT brigidamattia reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT venutochiara reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT bianconelivia reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT calabreseemma reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT giannarellidiana reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases AT monteleonegiovanni reversibilityoffrailphenotypeinpatientswithinflammatoryboweldiseases |